Knowledge Translation in Glomerulonephritis: Successes in Translational Research From the Bench to Bedside

• Published in: Canadian Journal of Kidney Health and Disease Vol. 10; p. 20543581231191839
• Main Authors: Yau, Kevin, Wang, Carol, Al Batran, Rami, Macphee, Anne, Beaucage, Mary, Farragher, Janine F.
• Format: Book Review Journal Article
• Language: English
• Published: Los Angeles, CA SAGE Publications 01-01-2023; Sage Publications Ltd; SAGE Publishing
• Subjects: Clinical trials; Medical research; Narrative Review; clinical trials; glomerulonephritis; patient engagement; knowledge translation
• ISSN: 2054-3581; 2054-3581
• DOI: 10.1177/20543581231191839

Purpose of review:
Glomerulonephritis refers to a rare group of diseases characterized by glomerular inflammation, which collectively are a common cause of kidney failure. Until recently, there was a lack of high-quality clinical trials to inform the care of patients with glomerulonephritides. We identified examples of successful translational research spanning from basic science to clinical applications, and highlight gaps in implementation science.
Sources of information:
The focus of our review was derived from discussions between health care professionals, researchers, and patient partners. We also performed literature searches pertaining to the treatment of glomerulonephritis in PubMed and Google Scholar.
Methods:
Examples of successful knowledge translation were generated through review of new evidence in the past 5 years and by iterative discussions by the authors. We then conducted a narrative review of several themes related to knowledge translation in glomerulonephritis. This was complemented by an interview with a patient partner to provide an example of a patient’s perspective living with glomerulonephritis.
Key findings:
We summarized selected recent advances in glomerulonephritis and its knowledge translation in the following domains: (1) identification of auto-antibodies in membranous nephropathy and minimal change disease; (2) clinical trials of novel targeted therapies for IgA nephropathy and lupus nephritis, which have led to approval of new treatments; (3) developments in research networks and clinical trials in glomerulonephritis; (4) recognition of the importance in developing standardized patient reported outcome measures in clinical trials; and (5) barriers in knowledge translation including access to medication.
Limitations:
A systematic search of the literature and formal assessment of quality of evidence were beyond the scope of this review.